Spravato billing is among the most complex in behavioral health – stacking drug codes, E/M visits, and extended observation on the same claim, inside a strict REMS compliance framework. Swift manages the full esketamine billing cycle so your clinic can focus on treatment, not paperwork.
At Swift Medical Billing, we specialize in Spravato billing for psychiatric clinics and behavioral health practices. Our comprehensive Spravato billing services cover pre-authorization management, REMS compliance, accurate coding, and denial processing. Maximize your esketamine reimbursements with minimal administrative burden.
End-to-end RCM for esketamine programs: eligibility verification, benefit routing confirmation (medical vs. pharmacy benefit), prior authorization, REMS compliance, coding, claim submission, and payment posting, managed as one workflow, not separate tasks.
Spravato denials follow predictable patterns: expired prior authorizations, insufficient REMS documentation, incorrect unit reporting, or code-to-diagnosis mismatches. Swift tracks root causes by payer and denial reason, appeals with detailed medical necessity documentation, and adjusts front-end workflows so the same denial does not recur.
Aged Spravato receivables often trace back to documentation gaps or authorization issues unresolved at submission. Swift audits the original claim, identifies what is missing (REMS observation records, PA documentation, correct NDC) and resubmits with complete supporting materials.
Regular audits verify time-based coding accuracy, REMS documentation completeness, and CPT/HCPCS code alignment for each payer. With the 2026 transition from S0013 to J0013, audits also confirm that legacy codes have been fully replaced across all active payers.
Our Spravato billing services are backed by extensive experience working with psychiatric practices and medication management. Swift ensures proper diagnostic coding, accurate documentation of clinical necessity, and compliance with payer requirements for Spravato billing. Psychiatrists receive fair reimbursement for esketamine therapy.
Providers must be certified through the Spravato REMS program before billing for esketamine. Swift manages enrollment, REMS certification verification, and payer credentialing to keep providers in-network and compliant with all current requirements.
Feel free to call us or contact us through our contact form. Please help us prepare by providing us with any details about your practice including practice model, specialty, and any specific concerns. Include the best time to contact you.
Swift Medical Billing has worked with various medical specialties, developed compliance and HIPAA programs from the ground up, and designed a streamlined process to suit individual practices. We are fully staffed with trained personnel; we have documented success in helping our clients become more profitable while alleviating the frustration of maintaining a billing department.
Yes! Swift Medical Billing is fully committed to compliance with clear standards of performance and education as well as the use of constructive discipline when and where necessary to maintain adherence to compliance policy and procedure. The Office of Inspector General (OIG) issued compliance guidance to third-party billing companies in 1998.
We provide comprehensive medical billing services, outsourced medical billing, credentialing, Virtual Front Office, billing audits, and revenue cycle management (RCM) for healthcare providers. Our services are tailored to meet the unique needs of your practice, ensuring accuracy and efficiency.
Yes! Swift Medical Solutions is fully committed to compliance with clear standards of performance and education as well as the use of constructive discipline when and where necessary to maintain adherence to compliance policy and procedure. The Office of Inspector General (OIG) issued compliance guidance to third-party billing companies in 1998.
More than 32% of Spravato claims are denied on first submission. The reasons are consistent: wrong HCPCS code, insufficient REMS documentation, prior authorization gaps, or incorrect unit reporting. These are not random errors. They follow predictable patterns that a billing team without dedicated esketamine experience will repeat month after month.
Spravato billing requires coordinating three components on a single date of service: the drug (J0013 for non-Medicare, G2082 or G2083 for Medicare), the E/M visit, and extended supervision time. Each component ties to its own documentation requirement, payer rule, and coding logic. A single mismatch, such as the wrong NDC, insufficient monitoring notes, or a PA that expired between sessions, triggers a denial or a 30-45 day processing delay.
Swift’s Spravato billing team manages this as an integrated workflow, not as separate billing tasks. REMS compliance, prior authorization tracking, buy-and-bill reconciliation, and claim submission run in parallel so nothing falls through between steps.
Our Spravato billing services workflow is structured to ensure accuracy, efficiency, and complete transparency at every stage of the esketamine reimbursement cycle.
We verify insurance coverage, confirm benefit routing (medical vs. pharmacy), and check prior authorization requirements before the first session. For buy-and-bill practices, we confirm the plan accepts G codes and that the NDC matches the dispensed product.
We complete all REMS requirements: facility registration confirmation, consent form tracking, and two-hour post-administration observation records, before claims go out. Missing REMS documentation is one of the leading causes of Spravato denials.
PA tracking includes initial authorization, expiration monitoring, and reauthorization before treatment continues. An expired PA is a predictable denial. We track expiration dates across all active patients and initiate renewal before the gap occurs.
AAPC-certified coders apply the correct 2026 code set: J0013 (or G2082/G2083 for Medicare buy-and-bill), E/M codes based on documented time, and prolonged service codes where applicable. Claims submit within 24-48 hours with full documentation attached.
Every claim is tracked through to payer confirmation. Denials are worked within 48 hours, with root cause documented and upstream workflows adjusted to prevent recurrence.
Swift provides Spravato billing support across all 50 states. We assist psychiatric clinics and behavioral health providers everywhere, from major cities to remote practices, ensuring compliance, faster claims, and reliable reimbursements.
We review your current Spravato claims, denial patterns, code usage, and REMS documentation workflow and show you exactly where reimbursement is being lost. Free, no commitment, findings are yours to keep.
Effective January 1, 2026, CMS discontinued S0013 and replaced it with J0013. Claims using S0013 for dates of service on or after January 1, 2026 are rejected. The working code set for 2026:
| Code | Description | Notes |
|---|---|---|
| J0013 | Esketamine, nasal spray, 1 mg | New HCPCS code replacing S0013. Bill units = total mg administered (56 mg = 56 units) |
| G2082 | E/M visit with up to 56 mg esketamine, includes 2-hour observation | Medicare bundled code, use when practice supplies the drug (buy-and-bill) |
| G2083 | E/M visit with more than 56 mg esketamine, includes 2-hour observation | Medicare bundled code for higher dose (typically 84 mg) |
| J3490 | Unclassified drug | Transitional code for payers that have not yet recognized J0013 |
| 99417 / G2212 | Prolonged service, each additional 15 minutes | Used when observation extends beyond the standard E/M time threshold |
Overall Rating
4.9
124 Reviews
The primary drug code for 2026 is J0013 (esketamine, nasal spray, 1 mg), which replaced S0013 effective January 1, 2026. For Medicare buy-and-bill, use bundled G codes: G2082 for doses up to 56 mg and G2083 for doses over 56 mg, both of which include the E/M visit and two-hour post-administration observation. Non-Medicare payers may or may not accept G codes. Always verify payer-specific coding policy before submission.
Over 32% of Spravato claims are denied on first submission. The most common causes are: expired or missing prior authorization, incorrect unit reporting on J0013 (units must equal total milligrams, not number of devices), insufficient REMS observation documentation, NDC mismatch on buy-and-bill claims, and using S0013 after the January 1, 2026 discontinuation date. Most of these are preventable with a properly structured front-end workflow.
REMS stands for Risk Evaluation and Mitigation Strategy. Because of the risks of sedation, dissociation, and potential for abuse, Spravato can only be administered at certified REMS treatment centers under direct provider supervision. Every claim must be backed by REMS-compliant documentation: facility certification, patient consent, and a documented two-hour post-administration observation period. Payers audit for this documentation and deny claims where it is incomplete.
In the buy-and-bill model, the practice purchases Spravato directly from a specialty distributor, administers it, and bills the payer for both the drug and the service. For Medicare, this uses bundled G codes. In the specialty pharmacy model, the pharmacy handles the drug cost and bills separately. The practice bills only the administration and observation components on the medical side, typically using E/M codes. Each model has different coding rules, and some payers mandate one approach over the other.
Most practices are fully onboarded within 30 days. Swift integrates with your existing EHR, confirms your REMS certification status, reviews current prior authorizations, and audits any outstanding claims before taking over submission. During transition, we handle aged Spravato A/R from your previous billing setup to maintain cash flow continuity.
Swift Medical Billing
Allows caregivers to focus 100% on patient’s needs by managing insurance billing and payments.
Address:
395 SW Bluff Dr, Suite 10 (lower level),
Bend OR 97702
Phone:
Email:
© 2025 Swift Medical Solutions, LLC. All rights reserved.